Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anika TherapeuticsANIK -3.60%64 Buyback Yield % is 4.28 as of Jul. 19, 2026, which is 6% above its 10-year median of 4.04. GuruFocus rates ANIK with a GF Score™ of 64/100 and a GF Value™ of $20.63 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 291 Drug Manufacturers companies, Anika Therapeutics ranks better than 95.19% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Anika Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANIK vs LFCR, DERM, ASRT: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (ANIK) has a Buyback Yield % of 4.28 as of Jul. 19, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Anika Therapeutics and its competitors. This is near median its historical median of 4.04. Over the past decade, Anika Therapeutics' Buyback Yield % has ranged from 0.36 to 8.86. According to the industry distribution chart, Anika Therapeutics ranks #14 out of 291 companies in the Drug Manufacturers industry, placing it in the top 4.8%.
Is Anika Therapeutics' Buyback Yield % too high?
Anika Therapeutics' current Buyback Yield % of 4.28 is near median its 10-year median of 4.04. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 8.86. Based on the distribution chart, Anika Therapeutics ranks #14 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anika Therapeutics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Buyback Yield % compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #14 out of 291 companies for Buyback Yield %. This places Anika Therapeutics in the top 5% of its industry — outperforming the majority of peers. Historically, Anika Therapeutics' own Buyback Yield % has ranged from 0.36 to 8.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Buyback Yield % is 4.28, which is near median its own 10-year median of 4.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.63, compared to a current price of $15.27 — trading 26% below its estimated fair value. The current Buyback Yield % is 4.28, which is near median its 10-year median of 4.04. Anika Therapeutics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current Buyback Yield % is 4.28 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of $15.27 is trading 26% below its estimated GF Value™ of $20.63.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for ANIK:
Buyback Yield %: 4.28 (near median its 10-year median of 4.04)
GF Value™: $20.63 vs. price of $15.27 (26% below fair value)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
64GF Score
Get the complete analysis for ANIK
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 
